DeepMed Research

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Telbivudine

First Posted Date: 2008-03-28

Last Posted Date: 2017-06-22

Lead Sponsor: Novartis

Target Recruit Count: 150

Registration Number: NCT00646503

Locations: 🇨🇳
Novartis Investigative Site, Beijing, China

Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Cell culture-derived influenza subunit vaccine (cTIV)
Biological: Egg derived influenza subunit vaccine (eTIV)

First Posted Date: 2008-03-27

Last Posted Date: 2015-11-23

Lead Sponsor: Novartis

Target Recruit Count: 3604

Registration Number: NCT00645411

Locations: 🇭🇷
Site 43: Spec. Pediatric Dispensary, Sisak, Croatia
🇫🇮
Site 67: Lahden rokotetutkimusklinikka, Lahti, Finland
🇫🇮
Site 68: Porin rokotetutkimusklinikka, Pori, Finland

and more 57 locations

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Biological: Adjuvanted trivalent inactivated subunit influenza vaccine
Biological: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
Biological: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine

First Posted Date: 2008-03-26

Last Posted Date: 2015-09-18

Lead Sponsor: Novartis

Target Recruit Count: 4902

Registration Number: NCT00644059

Locations: 🇫🇮
East Vantaa Clinic, East Vaanta, Finland
🇫🇮
Jarvenpaa Vaccine Research Clinic, Jarvenpaa, Finland
🇫🇮
Kokkola Vaccine Research Clinic, Kokkola, Finland

and more 98 locations

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

Phase 4

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Carbidopa/levodopa/entacapone
Drug: Immediate release carbidopa/levodopa

First Posted Date: 2008-03-25

Last Posted Date: 2011-02-18

Lead Sponsor: Novartis

Target Recruit Count: 14

Registration Number: NCT00642356

Locations: 🇺🇸
University of California, Irvine, California, United States
🇺🇸
Central New York Research Corporation, Syracuse, New York, United States
🇺🇸
Sunrise Clinical Research, Inc, Hollywood, Florida, United States

and more 18 locations

A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Phase 4

Completed

Conditions: Asthma

Interventions: Biological: omalizumab

First Posted Date: 2008-03-20

Last Posted Date: 2016-09-29

Lead Sponsor: Novartis

Target Recruit Count: 48

Registration Number: NCT00639691

Locations: 🇨🇦
Novartis Investigative Site, Montreal, Quebec, Canada

Safety of Lumiracoxib in Patients With Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis

Interventions: Device: lumiracoxib
Drug: rofecoxib

First Posted Date: 2008-03-18

Last Posted Date: 2008-03-18

Lead Sponsor: Novartis

Target Recruit Count: 309

Registration Number: NCT00637949

An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 300μg
Drug: Placebo

First Posted Date: 2008-03-17

Last Posted Date: 2011-08-30

Lead Sponsor: Novartis

Target Recruit Count: 27

Registration Number: NCT00636961

Locations: 🇩🇪
Novartis Investigator Site, Wiesbaden, Germany

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Phase 1

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Vildagliptin

First Posted Date: 2008-03-12

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis

Target Recruit Count: 22

Registration Number: NCT00633997

Locations: 🇺🇸
Novartis Investigator Site, Baltimore, Maryland, United States

Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin

Phase 3

Completed

Conditions: Pseudomonas Infections

Interventions: Drug: tobramycin

First Posted Date: 2008-03-12

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis

Target Recruit Count: 50

Registration Number: NCT00634192

Locations: 🇩🇪
Novartis Investigator Site, Munich, Germany
🇩🇪
Novartis Investigator site, Halle/Saale, Germany

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Ramipril
Other: Placebo to Aliskiren
Other: Placebo to Ramipril

First Posted Date: 2008-03-10

Last Posted Date: 2011-07-12

Lead Sponsor: Novartis

Target Recruit Count: 774

Registration Number: NCT00631917

Locations: 🇪🇸
Investigative Site, Investigative Site, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy